Developer docs
API playgroundTry for free, no card

Search company profiles

Eneapharm

Full company profile

uuid02m4wdb

Namestring
Eneapharm
Legal namestring
ENEAPHARM SAS
Websiteurl
eneapharm.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLabège, France
HQ citystring
Labège
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enzyme replacement therapy, exocrine pancreatic insufficiency, biopharmaceutical drug delivery, gastrointestinal therapeutics, orphan drug development
Product category
Pancreatic Enzyme Replacement Therapy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Eneapharm's primary revenue model will be derived from the sale of prescription pharmaceutical products upon regulatory approval. The company is developing a pipeline of therapeutic candidates for exocrine pancreatic insufficiency (EN311, EN3102, EN3103, EN3104) targeting both adult and pediatric populations.

eneapharm.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eneapharm is a clinical-stage biopharmaceutical company developing oral enzyme formulations for the treatment of exocrine pancreatic insufficiency (EPI). Its proprietary drug delivery technology enables targeted enzymatic release in the duodenum, and the pipeline comprises four candidates — EN311, EN3102, EN3103, and EN3104 — addressing adult, pediatric, and nasogastric patient populations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Approximately 70% of current treatments are inadequate due to slow enzyme release
+2 more records
Product overview1 text field

Eneapharm is a biopharmaceutical company developing innovative treatments for exocrine pancreatic insufficiency (EPI). The company's core portfolio includes four product candidates (EN311, EN3102, EN3103, EN3104) using a breakthrough formulation technology that enables targeted enzymatic release in the duodenum, overcoming limitations of current treatments. EN311 is the lead adult oral formulation, EN3102 targets pediatric patients, EN3103 is a first-in-class nasogastric form, and EN3104 focuses on bioavailability improvement. Products are available in multiple formulations including capsules, sticks, orodispersible tablets for adults and syrups for pediatric patients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-27
Description

GMP Clinical Manufacturing Partnership for EN311. Skyepharma, a fully integrated CDMO (Contract Development and Manufacturing Organization), provides expertise in clinical batch manufacturing for EN311. This collaboration supports Eneapharm's commitment to optimizing development processes, enhancing operational excellence, and delivering high-quality pharmaceutical products. David Lescuyer and Benoit Mougeot from Skyepharma played key roles in establishing the partnership.

Strategic tierMinorTypeOthers
Description

Nubbo is a leading incubator supporting high-impact technological and societal innovations. Eneapharm joined the Nubbo incubation program to accelerate development, benefit from top-tier strategic support, and strengthen position within a vibrant innovation ecosystem.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Institutional laboratory partner. Research collaboration through CIFRE contracts for doctoral research. Alexis Bages conducted research via a CIFRE contract funded by Eneapharm in connection with INSA, resulting in scientific publications in the European Journal of Pharmaceutics and Biopharmaceutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Institutional laboratory partner. Critt (Centre de Ressources en Innovation et Technologie) provides research and technology development support for Eneapharm's formulation technology.

5CHU Toulouse
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Institutional partner. CHU Toulouse (Centre Hospitalier Universitaire) provides clinical research collaboration and healthcare expertise supporting Eneapharm's clinical development programs.

eneapharm.com
6Sicoval
Strategic tierMinorTypeOthers
Description

Local development agency for the Toulouse metropolitan area. Provides support for technology companies in the Sicoval region where Labège is located.

eneapharm.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Fully integrated CDMO and Eneapharm's GMP clinical manufacturing partner for EN311. Highly relevant as an ecosystem participant enabling Eneapharm's clinical supply chain.

TypeDirect peer
Description

European pharmaceutical company with PERT and rare disease franchises including Pertyze; competes with Eneapharm in the EPI enzyme replacement market, particularly across EU geographies.

TypeDirect peer
Description

Markets Creon, the leading pancreatic enzyme replacement therapy (PERT) and the dominant incumbent in the EPI space. Directly competes with Eneapharm's EN311 in the same patient population and prescriber base.

TypeDirect peer
Description

Markets Pertzye, a PERT product now under Perrigo, targeting similar cystic fibrosis and chronic pancreatitis EPI populations as Eneapharm's EN311 and EN3102.

TypeBroad incumbent
Description

Global rare disease and GI pharma major following the Shire acquisition. Shire's former commercial leadership on Eneapharm's board reinforces the relevance of Takeda/Shire as a comparable strategic acquirer and broad PERT/rare disease incumbent.

TypeEmerging player
Description

Clinical-stage rare disease biopharmaceutical company with a similar go-to-market model of scientific publication, conference presence, and pharma partnership. Comparable in stage and disease-area specialisation, though in different therapeutic categories.

TypeDirect peer
Description

Markets Zenpep and Viokace, established PERT products competing directly with Eneapharm's pipeline for the same EPI indications and physician specialty channels.

TypeDirect peer
Description

Sells generic and authorised generic PERT products globally. Competes with Eneapharm on price and formulary access in the same EPI prescriber and payer channels.

TypeEmerging player
Description

Specialty pharma focused on rare nephrology and orphan indications, with comparable European clinical-stage profile. Eneapharm board member Ludovic Robin previously served as CBSO at Advicenne, evidencing operational and strategic parallels.

TypeBroad incumbent
Description

Specialty pharma with a strong gastroenterology and reproductive health portfolio, including prior PERT-related work. Eneapharm's QC/QA Director Pascal Bour previously held roles at Ferring, evidencing deep familiarity with the franchise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eneapharm

Pancreatic Enzyme Replacement Therapyeneapharm.com

Eneapharm firmographics

Firmographics
Name
Eneapharm
Legal name
ENEAPHARM SAS
Website
https://eneapharm.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Eneapharm is headquartered

Location

Headquarters

HQ city
Labège
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Eneapharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, Eneapharm's primary revenue model will be derived from the sale of prescription pharmaceutical products upon regulatory approval. The company is developing a pipeline of therapeutic candidates for exocrine pancreatic insufficiency (EN311, EN3102, EN3103, EN3104) targeting both adult and pediatric populations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Eneapharm product offering

Product offering

Core offering

Eneapharm is a clinical-stage biopharmaceutical company developing oral enzyme formulations for the treatment of exocrine pancreatic insufficiency (EPI). Its proprietary drug delivery technology enables targeted enzymatic release in the duodenum, and the pipeline comprises four candidates — EN311, EN3102, EN3103, and EN3104 — addressing adult, pediatric, and nasogastric patient populations.

Product overview

Eneapharm is a biopharmaceutical company developing innovative treatments for exocrine pancreatic insufficiency (EPI). The company's core portfolio includes four product candidates (EN311, EN3102, EN3103, EN3104) using a breakthrough formulation technology that enables targeted enzymatic release in the duodenum, overcoming limitations of current treatments. EN311 is the lead adult oral formulation, EN3102 targets pediatric patients, EN3103 is a first-in-class nasogastric form, and EN3104 focuses on bioavailability improvement. Products are available in multiple formulations including capsules, sticks, orodispersible tablets for adults and syrups for pediatric patients.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Approximately 70% of current treatments are inadequate due to slow enzyme release
  • +2 more outcomes

Companies that use Eneapharm

Customer profile

Segments5 records

Ideal customer profiles2 records

Eneapharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Eneapharm partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • SkyepharmacoreTechnology or Integration · 27 May 2025GMP Clinical Manufacturing Partnership for EN311. Skyepharma, a fully integrated CDMO (Contract Development and Manufacturing Organization), provides expertise in clinical batch manufacturing for EN311. This collaboration supports Eneapharm's commitment to optimizing development processes, enhancing operational excellence, and delivering high-quality pharmaceutical products. David Lescuyer and Benoit Mougeot from Skyepharma played key roles in establishing the partnership.
  • NubbominorOthersNubbo is a leading incubator supporting high-impact technological and societal innovations. Eneapharm joined the Nubbo incubation program to accelerate development, benefit from top-tier strategic support, and strengthen position within a vibrant innovation ecosystem.
  • INSA (Institut National des Sciences Appliquées)coreStrategic or Co-development PartnerInstitutional laboratory partner. Research collaboration through CIFRE contracts for doctoral research. Alexis Bages conducted research via a CIFRE contract funded by Eneapharm in connection with INSA, resulting in scientific publications in the European Journal of Pharmaceutics and Biopharmaceutics.
  • CrittcoreStrategic or Co-development PartnerInstitutional laboratory partner. Critt (Centre de Ressources en Innovation et Technologie) provides research and technology development support for Eneapharm's formulation technology.
  • CHU ToulousecoreStrategic or Co-development PartnerInstitutional partner. CHU Toulouse (Centre Hospitalier Universitaire) provides clinical research collaboration and healthcare expertise supporting Eneapharm's clinical development programs.
  • SicovalminorOthersLocal development agency for the Toulouse metropolitan area. Provides support for technology companies in the Sicoval region where Labège is located.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Eneapharm competitors and assessment

Company assessment

Others

  • Skyepharma: Fully integrated CDMO and Eneapharm's GMP clinical manufacturing partner for EN311. Highly relevant as an ecosystem participant enabling Eneapharm's clinical supply chain.

Direct peers

  • Chiesi Farmaceutici: European pharmaceutical company with PERT and rare disease franchises including Pertyze; competes with Eneapharm in the EPI enzyme replacement market, particularly across EU geographies.
  • AbbVie: Markets Creon, the leading pancreatic enzyme replacement therapy (PERT) and the dominant incumbent in the EPI space. Directly competes with Eneapharm's EN311 in the same patient population and prescriber base.
  • Digestive Care (Pertzye): Markets Pertzye, a PERT product now under Perrigo, targeting similar cystic fibrosis and chronic pancreatitis EPI populations as Eneapharm's EN311 and EN3102.
  • Nestle Health Science: Markets Zenpep and Viokace, established PERT products competing directly with Eneapharm's pipeline for the same EPI indications and physician specialty channels.
  • Viatris: Sells generic and authorised generic PERT products globally. Competes with Eneapharm on price and formulary access in the same EPI prescriber and payer channels.

Broad incumbents

  • Takeda Pharmaceutical: Global rare disease and GI pharma major following the Shire acquisition. Shire's former commercial leadership on Eneapharm's board reinforces the relevance of Takeda/Shire as a comparable strategic acquirer and broad PERT/rare disease incumbent.
  • Ferring Pharmaceuticals: Specialty pharma with a strong gastroenterology and reproductive health portfolio, including prior PERT-related work. Eneapharm's QC/QA Director Pascal Bour previously held roles at Ferring, evidencing deep familiarity with the franchise.

Emerging players

  • Alnylam Pharmaceuticals: Clinical-stage rare disease biopharmaceutical company with a similar go-to-market model of scientific publication, conference presence, and pharma partnership. Comparable in stage and disease-area specialisation, though in different therapeutic categories.
  • Advicenne Pharma: Specialty pharma focused on rare nephrology and orphan indications, with comparable European clinical-stage profile. Eneapharm board member Ludovic Robin previously served as CBSO at Advicenne, evidencing operational and strategic parallels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Eneapharm social profiles

Digital presence

Eneapharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eneapharm leadership team

Management profile

Number of profiles

Profiles7 records

Eneapharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eneapharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eneapharm

What does Eneapharm do?

Eneapharm is a clinical-stage biopharmaceutical company developing oral enzyme formulations for the treatment of exocrine pancreatic insufficiency (EPI). Its proprietary drug delivery technology enables targeted enzymatic release in the duodenum, and the pipeline comprises four candidates — EN311, EN3102, EN3103, and EN3104 — addressing adult, pediatric, and nasogastric patient populations.

Is Eneapharm a public or private company?

Eneapharm is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eneapharm founded?

Eneapharm was founded in 2018. It employs 1 to 10 people.

Where is Eneapharm based?

Eneapharm is headquartered in Labège, France, in the Europe region.

How does Eneapharm make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Eneapharm's main competitors?

Skyepharma is listed as an others. Direct peers are Chiesi Farmaceutici, AbbVie, Digestive Care (Pertzye), Nestle Health Science and Viatris. Broad incumbents are Takeda Pharmaceutical and Ferring Pharmaceuticals. Emerging players are Alnylam Pharmaceuticals and Advicenne Pharma.

Does Eneapharm have an API?

No public API is recorded for Eneapharm.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales